SENSEX
NIFTY
GOLD
USD/INR

Weather

image 17    C

National News

The Economic Times

National / The Economic Times

details

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

Gilead will pay $115 per share in cash at the deal's closing, which is at a premium of 79% to the stock's last close. Kite Pharma, a unit ?of Gilead Sciences, was partnering with Arcellx ?to jointly develop and sell anito-cel, an experimental CAR-T therapy for multiple myeloma, a type of blood cancer.

24 Feb 2026 12:33 am